PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDaunorubicin hydrochloride
Daunorubicin hydrochloride
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
464 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95881551101922352
Myeloid leukemia acuteD015470—C92.07711167416241
Myeloid leukemiaD007951—C92709761311211
Precursor cell lymphoblastic leukemia-lymphomaD054198——1358471414138
Lymphoid leukemiaD007945—C91949371210110
LymphomaD008223—C85.9926142148
Philadelphia chromosomeD010677——21022—14
Promyelocytic leukemia acuteD015473—C92.4—433111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190—D46152618—356
PreleukemiaD011289——111617—241
SyndromeD013577——81113—231
Non-hodgkin lymphomaD008228—C85.94129—126
NeoplasmsD009369—C80894—221
CarcinomaD002277—C80.0652——12
Myeloproliferative disordersD009196—D47.1364——12
RecurrenceD012008——651—111
Neoplasm metastasisD009362EFO_0009708—335—111
SarcomaD012509——435——10
Show 59 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403—C83.363———7
B-cell lymphomaD016393——54———7
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—35———6
Hodgkin diseaseD006689—C8123———5
Blast crisisD001752——13———4
Urinary bladder neoplasmsD001749—C67—3———3
Biphenotypic leukemia acuteD015456—C95.021——13
Residual neoplasmD018365———2——13
Transitional cell carcinomaD002295———2———2
Primary myelofibrosisD055728—D47.421———2
Show 28 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic neoplasmsD019337——5————5
Ovarian neoplasmsD010051EFO_0003893C563————3
Lung neoplasmsD008175HP_0100526C34.902————2
Fallopian tube neoplasmsD005185——2————2
Burkitt lymphomaD002051—C83.72————2
Stomach neoplasmsD013274EFO_0003897C162————2
Ovarian epithelial carcinomaD000077216——2————2
Prostatic neoplasmsD011471—C611————1
Castration-resistant prostatic neoplasmsD064129——1————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Show 26 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtaxiaD001259—R27.0————11
Ataxia telangiectasiaD001260Orphanet_100G11.3————11
TelangiectasisD013684——————11
Cerebellar ataxiaD002524HP_0001251—————11
HivD006678——————11
CardiomyopathiesD009202EFO_0000318I42————11
Induction chemotherapyD060828——————11
Eye abnormalitiesD005124HP_0000478Q15.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
No data
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 281 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,150 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use